C07K 16/2878
Against the ngf-receptor/tnf-receptor superfamily
Official title: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
C07K16/2878 (Against the ngf-receptor/tnf-receptor superfamily) appears on 1,952 US grants and 4,303 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,952
- Published applications
- 4,303
- Assignees
- 1,142
- Inventors
- 6,748
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 7 | 0 |
| 1998 | 7 | 0 |
| 1999 | 10 | 0 |
| 2000 | 12 | 0 |
| 2001 | 14 | 4 |
| 2002 | 15 | 35 |
| 2003 | 11 | 56 |
| 2004 | 12 | 46 |
| 2005 | 18 | 68 |
| 2006 | 17 | 63 |
| 2007 | 20 | 77 |
| 2008 | 23 | 60 |
| 2009 | 33 | 87 |
| 2010 | 40 | 92 |
| 2011 | 29 | 86 |
| 2012 | 41 | 82 |
| 2013 | 46 | 87 |
| 2014 | 47 | 109 |
| 2015 | 61 | 96 |
| 2016 | 66 | 134 |
| 2017 | 74 | 161 |
| 2018 | 82 | 206 |
| 2019 | 115 | 272 |
| 2020 | 166 | 335 |
| 2021 | 156 | 344 |
| 2022 | 171 | 389 |
| 2023 | 149 | 402 |
| 2024 | 160 | 396 |
| 2025 | 216 | 360 |
| 2026 | 131 | 256 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Anti-tumor necrosis factor receptor (TNFR2) antibodies and uses thereof6 Oct 2026US 12,753,240 B2Biolojic Design Ltd.
- Multi-specific antibodies binding to BCMA29 Sep 2026US 12,747,298 B2TeneoBio, Inc.
- CD40 binding molecules and uses thereof29 Sep 2026US 12,747,299 B2Memorial Sloan Kettering Cancer Center
- Multi-receptor natural killer cells8 Oct 2026US 2026/0308225 A1Board of Regents, The University of Texas System
- Anti-ox40 antibody and uses thereof8 Oct 2026US 2026/0308267 A1Hutchison Medipharma Limited
- Immunotherapeutic proteins8 Oct 2026US 2026/0308271 A1Macfarlane Burnet Institute for Medical Research and Public Health Limited
- Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse8 Oct 2026US 2026/0308532 A1Fred Hutchinson Cancer Center
- Chimeric antigen receptor targeting bcma and use thereof1 Oct 2026US 2026/0295044 A1Shenzhen Cell Valley Biomedical Co., Ltd.
Most cited
By later US patents
- Simultaneous stimulation and concentration of cells422US 6,797,514 B2XCYTE Therapies, Inc. · 2004
- Simultaneous stimulation and concentration of cells398US 6,867,041 B2XCYTE Therapies, Inc. · 2005
- Simultaneous stimulation and concentration of cells383US 6,905,874 B2XCYTE Therapies, Inc. · 2005
- Chimeric receptors with 4-1BB stimulatory signaling domain329US 8,399,645 B2St. Jude Children?S Research Hospital · 2013
- Frozen piercing implements and methods for piercing a substrate284US 8,784,385 B2The Invention Science Fund I, LLC · 2014